Atogepant: A Breakthrough for Treatment-Resistant Migraines

Research Summary

A recent study published in Cephalalgia has highlighted the effectiveness of Atogepant, a novel oral CGRP receptor antagonist, for preventing migraines in a treatment-resistant population. Conducted across 15 headache units in Spain, the study included 513 patients, predominantly women with an average age of 48. Over three months, patients experienced significant reductions in headache and migraine days, with 34% achieving a ≥50% reduction in headache days and 29% in migraine days. Common mild side effects included constipation (30%) and nausea (18%), with a 12% discontinuation rate. Results suggest Atogepant's potential for meaningful improvement, particularly with early intervention.

Study Details

📄 Title: Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).

👥 Research Team: Gago-Veiga AB et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2026 Apr

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.